Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MDLive vs Mevo Health

MDLive
Graded #357

Lower grade

vs+1.4000000000000057
Mevo Health
Graded #327

Higher grade

The verdict

Mevo Health takes it — 60.2/100 to 58.8/100, but only just.

Mevo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu. MDLive is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMevo Health +11
45
56
Dose & formulationMevo Health +30
53
83
Clinical oversightMDLive +18
85
67
Labs & monitoringMDLive +2
54
52
FulfillmentMDLive +5
62
57
Contract termsMDLive +35
55
20
MDLive · left barMevo Health · right bar

The numbers

MetricMDLiveMevo Health
WeighScore58.8/10060.2/100
GradeCC
Scorecard rank#357#327
SemaglutideNot disclosed$199/mo (all doses, compounded)
TirzepatideNot disclosed$259/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
MDLive

Graded #357 · C

Strengths

  • Prescribes FDA-approved branded GLP-1s including Wegovy and Zepbound
  • Covered through insurance and employer benefits for 50M-plus people
  • Board-certified physicians averaging about 15 years of experience
  • Part of Evernorth/Cigna, a large established healthcare organization
  • Offers full primary care, not just a single weight-loss funnel

Where it loses points

  • GLP-1s only at clinician discretion in a Primary Care routine visit
  • Anti-obesity meds not available in FL, LA, MS or NJ
  • Distributed mainly via insurers and employers; cost varies by plan
  • No transparent published monthly cash price for GLP-1 care
Mevo Health

Graded #327 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard